Table 1.
Effects of cyclosporin A (CsA) on the gene expression associated with cardiac hypertrophy-induced by potassium bromate (KBrO3) in H9c2 cells.
| Contents | Control | Vehicle + KBrO3 (250 μM) | CsA (0.5 μM) + KBrO3 (250 μM) | CsA (1 μM) + KBrO3 (250 μM) |
|---|---|---|---|---|
| Relative mRNA of ANP/β-Actin | 1.00 ± 0.00 | 1.87 ± 0.09** | 1.49 ± 0.09*# | 0.99 ± 0.02# |
| Relative mRNA of BNP/β-Actin | 1.00 ± 0.00 | 1.90 ± 0.13** | 1.45 ± 0.14*# | 0.85 ± 0.08# |
| Relative mRNA of UBE3A/β-Actin | 1.00 ± 0.00 | 1.80 ± 0.18** | 1.15 ± 0.14*# | 0.68 ± 0.13# |
| Ratio of calcineurin/β-Actin protein | 0.33 ± 0.06 | 1.04 ± 0.05** | 0.67 ± 0.05*# | 0.37 ± 0.05# |
| Ratio of NFAT3/Histone H3 protein | 0.30 ± 0.03 | 0.69 ± 0.06** | 0.48 ± 0.03*# | 0.32 ± 0.04# |
| Ratio of UBE3A/β-Actin protein | 0.41 ± 0.04 | 0.86 ± 0.04** | 0.52 ± 0.02*# | 0.46 ± 0.03# |
Values (mean ± SEM) were obtained from six samples per group. Effects of CsA at indicated concentration were compared with that treated with vehicle.
*
P < 0.05 or
**
P < 0.01 significantly different from the control.
#
P < 0.05 varied with the vehicle-treated group.